Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov:119:113-122.
doi: 10.1016/j.critrevonc.2017.10.001. Epub 2017 Oct 4.

Advances in the management of HER2-positive early breast cancer

José Baselga  1 , Robert E Coleman  2 , Javier Cortés  3 , Wolfgang Janni  4
Affiliations
Review

Advances in the management of HER2-positive early breast cancer

José Baselga et al. Crit Rev Oncol Hematol. 2017 Nov.

Abstract

While trastuzumab is firmly established as the cornerstone of therapy for both early and advanced breast cancer expressing human epidermal growth factor receptor 2 (HER2), many patients either do not respond to trastuzumab treatment or progress following therapy. Improved understanding of breast cancer biology, particularly the complex signaling interactions managed by the HER family of receptors, have resulted in development of several novel HER2-directed therapies and combinations. This article will review the novel approaches to HER2 targeting that have been developed in recent years, with particular focus on results from these approaches in early breast cancer, and will discuss strategies to improve the tolerability of HER2-directed therapies, including prevention of cardiac toxicity and diarrhea.

Keywords: Breast cancer; HER2; Lapatinib; Neratinib; Pertuzumab; T-DM1; Trastuzumab.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

José Baselga has disclosed that he has received consulting fees from Eli Lilly, Grail Inc., and Novartis. He also has ownership interest in Grail, Inc., Infinity Pharmaceuticals, Juno Therapeutics, and PMV Pharma. He has also disclosed leadership roles in Infinity Pharmaceuticals and Varian Medical Systems.

Robert E. Coleman has disclosed that he has performed contracted research for Bayer and Celgene, and he has given expert testimony for Novartis.

Javier Cortés has disclosed that he has received consulting fees from AstraZeneca, Biothera, Celgene, Cellestia Biotech, Roche. He has also received fees for non-CME services directly from Celgene, Eisai, Novartis, Pfizer, and Roche.

Wolfgang Janni has disclosed that he has received consulting fees from Amgen, AstraZeneca, Eisai, MSD, Novartis, Pfizer, and Roche. He has also performed contracted research for Amgen, AstraZeneca, Eisai, MSD, Novartis, Pfizer, and Roche.

Figures

Fig. 1
Fig. 1
Targets of novel HER2 inhibitors.
Fig. 2
Fig. 2
Response to neratinib in patients with HER2-mutated breast cancer on the SUMMIT trial. PFS, progression-free survival (Hyman et al., 2017).
See this image and copyright information in PMC

References

    1. AGO Website. Guidelines of the AGO Breast Committee: Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. 2017 http://www.agoonline.de/fileadmin/downloads/leitlinien/mamma/2017-03/AGO... (Accessed July 1, 2017)
    1. Andre F, O’Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15:580–591. - PubMed
    1. Arpino G, Gerrero JM, de la Haba-Rodriguez J, Easton V, Schuhmacher C, Restuccia E, et al. 2016 San Antonio Breast Cancer Symposium. San Antonio, TX: 2016. Dec 6–10, Primary analysis of PERTAIN: A randomized, two-arm, open-label, multicentre phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer. Abstract S3–04.
    1. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012a;366:109–119. - PMC - PubMed
    1. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomized, open-label, multicenter, phase 3 trial. Lancet. 2012b;379:633–640. - PMC - PubMed

MeSH terms